世界の遺伝子組み換えサブユニットワクチン市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Gene Engineered Subunit Vaccine Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z2511
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、93ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、遺伝子組み換えサブユニットワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（治療用遺伝子組み換えサブユニットワクチン、予防用遺伝子組み換えサブユニットワクチン）、用途別市場規模（人間用、動物用）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・遺伝子組み換えサブユニットワクチンの市場動向
・企業の競争状況、市場シェア
・遺伝子組み換えサブユニットワクチンの種類別市場規模（治療用遺伝子組み換えサブユニットワクチン、予防用遺伝子組み換えサブユニットワクチン）
・遺伝子組み換えサブユニットワクチンの用途別市場規模（人間用、動物用）
・遺伝子組み換えサブユニットワクチンの北米市場規模2016-2027（アメリカ、カナダ）
・遺伝子組み換えサブユニットワクチンのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・遺伝子組み換えサブユニットワクチンのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・遺伝子組み換えサブユニットワクチンの中南米市場規模2016-2027（メキシコ、ブラジル）
・遺伝子組み換えサブユニットワクチンの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Merck、GSK、Tiantan、Pulike、Greffex、CureVac、Yebio、Sanofi Pasteur SA、Virbac、Pfizer Inc.、Walvax Biotechnology、Kontec）
・結論

A gene engineered subunit vaccine or a bio-recombinant subunit vaccine refers to the expression of a protective antigen gene in a prokaryotic or eukaryotic cell, and a vaccine made from a gene product—protein or polypeptide.

Market Analysis and Insights: Global Gene Engineered Subunit Vaccine Market
The global Gene Engineered Subunit Vaccine market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Gene Engineered Subunit Vaccine market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Gene Engineered Subunit Vaccine market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Gene Engineered Subunit Vaccine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Gene Engineered Subunit Vaccine market.

Global Gene Engineered Subunit Vaccine Scope and Market Size
Gene Engineered Subunit Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Gene Engineered Subunit Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Therapeutic Gene Engineered Subunit Vaccine
Preventative Gene Engineered Subunit Vaccine

Segment by Application
Human Use
Veterinary Use

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Merck
GSK
Tiantan
Pulike
Greffex
CureVac
Yebio
Sanofi Pasteur SA
Virbac
Pfizer Inc.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Engineered Subunit Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Therapeutic Gene Engineered Subunit Vaccine
1.2.3 Preventative Gene Engineered Subunit Vaccine
1.3 Market by Application
1.3.1 Global Gene Engineered Subunit Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Human Use
1.3.3 Veterinary Use
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Gene Engineered Subunit Vaccine Market Perspective (2016-2027)
2.2 Gene Engineered Subunit Vaccine Growth Trends by Regions
2.2.1 Gene Engineered Subunit Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Gene Engineered Subunit Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Gene Engineered Subunit Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Gene Engineered Subunit Vaccine Industry Dynamic
2.3.1 Gene Engineered Subunit Vaccine Market Trends
2.3.2 Gene Engineered Subunit Vaccine Market Drivers
2.3.3 Gene Engineered Subunit Vaccine Market Challenges
2.3.4 Gene Engineered Subunit Vaccine Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Gene Engineered Subunit Vaccine Players by Revenue
3.1.1 Global Top Gene Engineered Subunit Vaccine Players by Revenue (2016-2021)
3.1.2 Global Gene Engineered Subunit Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Gene Engineered Subunit Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Gene Engineered Subunit Vaccine Revenue
3.4 Global Gene Engineered Subunit Vaccine Market Concentration Ratio
3.4.1 Global Gene Engineered Subunit Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Engineered Subunit Vaccine Revenue in 2020
3.5 Gene Engineered Subunit Vaccine Key Players Head office and Area Served
3.6 Key Players Gene Engineered Subunit Vaccine Product Solution and Service
3.7 Date of Enter into Gene Engineered Subunit Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Gene Engineered Subunit Vaccine Breakdown Data by Type
4.1 Global Gene Engineered Subunit Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Gene Engineered Subunit Vaccine Forecasted Market Size by Type (2022-2027)

5 Gene Engineered Subunit Vaccine Breakdown Data by Application
5.1 Global Gene Engineered Subunit Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Gene Engineered Subunit Vaccine Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Gene Engineered Subunit Vaccine Market Size (2016-2027)
6.2 North America Gene Engineered Subunit Vaccine Market Size by Type
6.2.1 North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
6.2.2 North America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
6.2.3 North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
6.3 North America Gene Engineered Subunit Vaccine Market Size by Application
6.3.1 North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
6.3.2 North America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
6.3.3 North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
6.4 North America Gene Engineered Subunit Vaccine Market Size by Country
6.4.1 North America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
6.4.2 North America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Gene Engineered Subunit Vaccine Market Size (2016-2027)
7.2 Europe Gene Engineered Subunit Vaccine Market Size by Type
7.2.1 Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
7.3 Europe Gene Engineered Subunit Vaccine Market Size by Application
7.3.1 Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
7.4 Europe Gene Engineered Subunit Vaccine Market Size by Country
7.4.1 Europe Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type
8.2.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application
8.3.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region
8.4.1 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Gene Engineered Subunit Vaccine Market Size (2016-2027)
9.2 Latin America Gene Engineered Subunit Vaccine Market Size by Type
9.2.1 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
9.3 Latin America Gene Engineered Subunit Vaccine Market Size by Application
9.3.1 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
9.4 Latin America Gene Engineered Subunit Vaccine Market Size by Country
9.4.1 Latin America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type
10.2.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application
10.3.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country
10.4.1 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Gene Engineered Subunit Vaccine Introduction
11.1.4 Merck Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.1.5 Merck Recent Development
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Gene Engineered Subunit Vaccine Introduction
11.2.4 GSK Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.2.5 GSK Recent Development
11.3 Tiantan
11.3.1 Tiantan Company Details
11.3.2 Tiantan Business Overview
11.3.3 Tiantan Gene Engineered Subunit Vaccine Introduction
11.3.4 Tiantan Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.3.5 Tiantan Recent Development
11.4 Pulike
11.4.1 Pulike Company Details
11.4.2 Pulike Business Overview
11.4.3 Pulike Gene Engineered Subunit Vaccine Introduction
11.4.4 Pulike Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.4.5 Pulike Recent Development
11.5 Greffex
11.5.1 Greffex Company Details
11.5.2 Greffex Business Overview
11.5.3 Greffex Gene Engineered Subunit Vaccine Introduction
11.5.4 Greffex Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.5.5 Greffex Recent Development
11.6 CureVac
11.6.1 CureVac Company Details
11.6.2 CureVac Business Overview
11.6.3 CureVac Gene Engineered Subunit Vaccine Introduction
11.6.4 CureVac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.6.5 CureVac Recent Development
11.7 Yebio
11.7.1 Yebio Company Details
11.7.2 Yebio Business Overview
11.7.3 Yebio Gene Engineered Subunit Vaccine Introduction
11.7.4 Yebio Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.7.5 Yebio Recent Development
11.8 Sanofi Pasteur SA
11.8.1 Sanofi Pasteur SA Company Details
11.8.2 Sanofi Pasteur SA Business Overview
11.8.3 Sanofi Pasteur SA Gene Engineered Subunit Vaccine Introduction
11.8.4 Sanofi Pasteur SA Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.8.5 Sanofi Pasteur SA Recent Development
11.9 Virbac
11.9.1 Virbac Company Details
11.9.2 Virbac Business Overview
11.9.3 Virbac Gene Engineered Subunit Vaccine Introduction
11.9.4 Virbac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.9.5 Virbac Recent Development
11.10 Pfizer Inc.
11.10.1 Pfizer Inc. Company Details
11.10.2 Pfizer Inc. Business Overview
11.10.3 Pfizer Inc. Gene Engineered Subunit Vaccine Introduction
11.10.4 Pfizer Inc. Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.10.5 Pfizer Inc. Recent Development
11.11 Walvax Biotechnology
11.11.1 Walvax Biotechnology Company Details
11.11.2 Walvax Biotechnology Business Overview
11.11.3 Walvax Biotechnology Gene Engineered Subunit Vaccine Introduction
11.11.4 Walvax Biotechnology Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.11.5 Walvax Biotechnology Recent Development
11.12 Kontec
11.12.1 Kontec Company Details
11.12.2 Kontec Business Overview
11.12.3 Kontec Gene Engineered Subunit Vaccine Introduction
11.12.4 Kontec Revenue in Gene Engineered Subunit Vaccine Business (2016-2021)
11.12.5 Kontec Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Gene Engineered Subunit Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Therapeutic Gene Engineered Subunit Vaccine
Table 3. Key Players of Preventative Gene Engineered Subunit Vaccine
Table 4. Global Gene Engineered Subunit Vaccine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Gene Engineered Subunit Vaccine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Gene Engineered Subunit Vaccine Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Gene Engineered Subunit Vaccine Market Share by Regions (2016-2021)
Table 8. Global Gene Engineered Subunit Vaccine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Gene Engineered Subunit Vaccine Market Share by Regions (2022-2027)
Table 10. Gene Engineered Subunit Vaccine Market Trends
Table 11. Gene Engineered Subunit Vaccine Market Drivers
Table 12. Gene Engineered Subunit Vaccine Market Challenges
Table 13. Gene Engineered Subunit Vaccine Market Restraints
Table 14. Global Gene Engineered Subunit Vaccine Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Gene Engineered Subunit Vaccine Market Share by Players (2016-2021)
Table 16. Global Top Gene Engineered Subunit Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Engineered Subunit Vaccine as of 2020)
Table 17. Ranking of Global Top Gene Engineered Subunit Vaccine Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Gene Engineered Subunit Vaccine Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Gene Engineered Subunit Vaccine Product Solution and Service
Table 21. Date of Enter into Gene Engineered Subunit Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Engineered Subunit Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2016-2021)
Table 25. Global Gene Engineered Subunit Vaccine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Gene Engineered Subunit Vaccine Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2016-2021)
Table 29. Global Gene Engineered Subunit Vaccine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Gene Engineered Subunit Vaccine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Gene Engineered Subunit Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Gene Engineered Subunit Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Gene Engineered Subunit Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Gene Engineered Subunit Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Gene Engineered Subunit Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Gene Engineered Subunit Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Gene Engineered Subunit Vaccine Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Gene Engineered Subunit Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Gene Engineered Subunit Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Gene Engineered Subunit Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Gene Engineered Subunit Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Gene Engineered Subunit Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Gene Engineered Subunit Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Gene Engineered Subunit Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 61. Merck Company Details
Table 62. Merck Business Overview
Table 63. Merck Gene Engineered Subunit Vaccine Product
Table 64. Merck Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 65. Merck Recent Development
Table 66. GSK Company Details
Table 67. GSK Business Overview
Table 68. GSK Gene Engineered Subunit Vaccine Product
Table 69. GSK Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 70. GSK Recent Development
Table 71. Tiantan Company Details
Table 72. Tiantan Business Overview
Table 73. Tiantan Gene Engineered Subunit Vaccine Product
Table 74. Tiantan Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 75. Tiantan Recent Development
Table 76. Pulike Company Details
Table 77. Pulike Business Overview
Table 78. Pulike Gene Engineered Subunit Vaccine Product
Table 79. Pulike Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 80. Pulike Recent Development
Table 81. Greffex Company Details
Table 82. Greffex Business Overview
Table 83. Greffex Gene Engineered Subunit Vaccine Product
Table 84. Greffex Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 85. Greffex Recent Development
Table 86. CureVac Company Details
Table 87. CureVac Business Overview
Table 88. CureVac Gene Engineered Subunit Vaccine Product
Table 89. CureVac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 90. CureVac Recent Development
Table 91. Yebio Company Details
Table 92. Yebio Business Overview
Table 93. Yebio Gene Engineered Subunit Vaccine Product
Table 94. Yebio Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 95. Yebio Recent Development
Table 96. Sanofi Pasteur SA Company Details
Table 97. Sanofi Pasteur SA Business Overview
Table 98. Sanofi Pasteur SA Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 99. Sanofi Pasteur SA Recent Development
Table 100. Virbac Company Details
Table 101. Virbac Business Overview
Table 102. Virbac Gene Engineered Subunit Vaccine Product
Table 103. Virbac Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 104. Virbac Recent Development
Table 105. Pfizer Inc. Company Details
Table 106. Pfizer Inc. Business Overview
Table 107. Pfizer Inc. Gene Engineered Subunit Vaccine Product
Table 108. Pfizer Inc. Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 109. Pfizer Inc. Recent Development
Table 110. Walvax Biotechnology Company Details
Table 111. Walvax Biotechnology Business Overview
Table 112. Walvax Biotechnology Gene Engineered Subunit Vaccine Product
Table 113. Walvax Biotechnology Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 114. Walvax Biotechnology Recent Development
Table 115. Kontec Company Details
Table 116. Kontec Business Overview
Table 117. Kontec Gene Engineered Subunit Vaccine Product
Table 118. Kontec Revenue in Gene Engineered Subunit Vaccine Business (2016-2021) & (US$ Million)
Table 119. Kontec Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Engineered Subunit Vaccine Market Share by Type: 2020 VS 2027
Figure 2. Therapeutic Gene Engineered Subunit Vaccine Features
Figure 3. Preventative Gene Engineered Subunit Vaccine Features
Figure 4. Global Gene Engineered Subunit Vaccine Market Share by Application: 2020 VS 2027
Figure 5. Human Use Case Studies
Figure 6. Veterinary Use Case Studies
Figure 7. Gene Engineered Subunit Vaccine Report Years Considered
Figure 8. Global Gene Engineered Subunit Vaccine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Gene Engineered Subunit Vaccine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Gene Engineered Subunit Vaccine Market Share by Regions: 2020 VS 2027
Figure 11. Global Gene Engineered Subunit Vaccine Market Share by Regions (2022-2027)
Figure 12. Global Gene Engineered Subunit Vaccine Market Share by Players in 2020
Figure 13. Global Top Gene Engineered Subunit Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gene Engineered Subunit Vaccine as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Gene Engineered Subunit Vaccine Revenue in 2020
Figure 15. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2016-2021)
Figure 16. Global Gene Engineered Subunit Vaccine Revenue Market Share by Type (2022-2027)
Figure 17. North America Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Gene Engineered Subunit Vaccine Market Share by Type (2016-2027)
Figure 19. North America Gene Engineered Subunit Vaccine Market Share by Application (2016-2027)
Figure 20. North America Gene Engineered Subunit Vaccine Market Share by Country (2016-2027)
Figure 21. United States Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Gene Engineered Subunit Vaccine Market Share by Type (2016-2027)
Figure 25. Europe Gene Engineered Subunit Vaccine Market Share by Application (2016-2027)
Figure 26. Europe Gene Engineered Subunit Vaccine Market Share by Country (2016-2027)
Figure 27. Germany Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Gene Engineered Subunit Vaccine Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Gene Engineered Subunit Vaccine Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Gene Engineered Subunit Vaccine Market Share by Region (2016-2027)
Figure 37. China Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Gene Engineered Subunit Vaccine Market Share by Type (2016-2027)
Figure 45. Latin America Gene Engineered Subunit Vaccine Market Share by Application (2016-2027)
Figure 46. Latin America Gene Engineered Subunit Vaccine Market Share by Country (2016-2027)
Figure 47. Mexico Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Gene Engineered Subunit Vaccine Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Gene Engineered Subunit Vaccine Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Gene Engineered Subunit Vaccine Market Share by Country (2016-2027)
Figure 53. Turkey Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Gene Engineered Subunit Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Merck Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 57. GSK Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 58. Tiantan Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 59. Pulike Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 60. Greffex Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 61. CureVac Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 62. Yebio Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 63. Sanofi Pasteur SA Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 64. Virbac Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 65. Pfizer Inc. Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 66. Walvax Biotechnology Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 67. Kontec Revenue Growth Rate in Gene Engineered Subunit Vaccine Business (2016-2021)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Global Covid-19 Vaccine Market Size, Status and Forecast 2021-2027
QYR2104Z1633 2021年4月 96Pages
QYResearch社発行の本調査資料では、新型コロナウイルス感染症ワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（DNA、非複製ウイルスベクター、タンパク質サブユニット、RNA、その他）、用途別市場規模（成人、子供）、主要地域別市場規...

世界の食用ワクチン市場規模・現状・予測（2021年-2027年）

Global Edible Vaccine Market Size, Status and Forecast 2021-2027
QYR2104Z2043 2021年4月 100Pages
QYResearch社発行の本調査資料では、食用ワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（不活化ワクチン、その他）、用途別市場規模（医療、畜産、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、イ...

世界の食用ワクチン市場規模・現状・予測（2021年-2027年）

世界のアデノウイルスベクターワクチン市場規模・現状・予測（2021年-2027年）

Global Adenovirus Vector Vaccine Market Size, Status and Forecast 2021-2027
QYR2104Z0097 2021年4月 98Pages
QYResearch社発行の本調査資料では、アデノウイルスベクターワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（開発中、前臨床、臨床I、臨床II）、用途別市場規模（製薬・バイオテクノロジー企業、病院、学術・研究機関、その他）、主要地域...

世界のムコ多糖症遺伝子治療市場規模・現状・予測（2021年-2027年）

Global Gene Therapy for Mucopolysaccharidosis Market Size, Status and Forecast 2021-2027
QYR2104Z2520 2021年4月 92Pages
QYResearch社発行の本調査資料では、ムコ多糖症遺伝子治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（静脈内、ICV、脳内、大槽内）、用途別市場規模（ムコ多糖症I型、ムコ多糖症II型、ムコ多糖症III型A型、ムコ多糖症型III型B型）...

世界の小児用ワクチン市場規模・現状・予測（2021年-2027年）

Global Paediatric Vaccine Market Size, Status and Forecast 2021-2027
QYR2104Z4404 2021年4月 92Pages
QYResearch社発行の本調査資料では、小児用ワクチンのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（肺炎球菌、水痘、混合、ポリオウイルス、肝炎、MMR、小児ホルモン、HIB、アレルギー＆呼吸器ワクチン、その他）、用途別市場規模（0～3、3...

世界のDNA遺伝子チップ市場規模・現状・予測（2021年-2027年）

Global DNA Gene Chip Market Size, Status and Forecast 2021-2027
QYR2104Z1940 2021年4月 94Pages
QYResearch社発行の本調査資料では、DNA遺伝子チップのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（CDNA（相補DNA）、ODNA（オリゴヌクレオチドDNA））、用途別市場規模（遺伝子発現、がん診断・治療、創薬、遺伝、その他）、主要...

世界の遺伝子発現市場規模・現状・予測（2021年-2027年）

Global Gene Expression Market Size, Status and Forecast 2021-2027
QYR2104Z2512 2021年4月 98Pages
QYResearch社発行の本調査資料では、遺伝子発現のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（消耗品、機器）、用途別市場規模（創薬、診断）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中...

世界のTBワクチン治療市場規模・現状・予測（2021年-2027年）

Global TB Vaccine Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z5562 2021年4月 99Pages
QYResearch社発行の本調査資料では、TBワクチン治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫ワクチン、治療ワクチン）、用途別市場規模（自己調達、ユニセフ、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本...

世界の加齢性黄斑変性症向け遺伝子治療市場規模・現状・予測（2021年-2027年）

Global Gene Therapy for Age-related Macular Degeneration Market Size, Status and Forecast 2021-2027
QYR2104Z2517 2021年4月 97Pages
QYResearch社発行の本調査資料では、加齢性黄斑変性症向け遺伝子治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（網膜下、硝子体内）、用途別市場規模（単剤療法、併用療法）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中...

世界の新型コロナウイルス感染症ワクチン市場規模・現状・予測（2021年-2027年） A COVID-19 vaccine is a hypothetical vaccine against coronavirus disease 2019 (COVID-19). Although no vaccine has completed clinical trials, there are multiple attempts in progress to develop such a vaccine. The genetic sequence of SARS-CoV-2, the coronavirus that causes COVID-19, was published on 1…
世界のムコ多糖症遺伝子治療市場規模・現状・予測（2021年-2027年） Mucopolysaccharidosis consists of a group of more than 40 genetic disorders that forms a part of lysosomal storage disease. They are caused by an inherited deficiency of an enzyme involved in the degradation of acid glycosaminoglycans (GAGs), which was previously known as mucopolysaccharidosis. All …
世界の遺伝子発現市場規模・現状・予測（2021年-2027年） Gene expression is the process by which information from a gene is used in the synthesis of a functional gene product. These products are often proteins, but in non-protein coding genes such as transfer RNA (tRNA) or small nuclear RNA (snRNA) genes, the product is a functional RNA. Market is expecte…
世界のDNA遺伝子チップ市場規模・現状・予測（2021年-2027年） DNA gene chips or DNA microarrays are tiny chips that are engrafted with DNA molecules. A DNA gene chip size resembles the size of a postage stamp. A DNA microarray consists of a set of microscopic DNA spots attached on a solid surface. Every DNA spot consists of picomoles of a definite DNA sequence…
世界の卵巣がん遺伝子治療市場規模・現状・予測（2021年-2027年） Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor…